Vol.1 No.1 -3 : Antitumor activity of two Streptomyces extracts (Ag18 & Ag20) on Ehrlich ascites tumor in mice in vitro and in vivo studies.

By : Amany A. Gaber1, Osama M. Badr , Saad A. Emara3, Atef M. Ibrahim

Abstract

This study aimed to evaluate the potent antitumor activity of metabolites from Streptomyces as antitumor activity using in vitro and in vivo studies. The Streptomyces were purely isolated from the soil samples, processed to obtain their extracts. Twenty Streptomyces extracts were obtained. Two isolates of Streptomyces were characterized morphologically, physiologically, biochemically and 16sr RNA and they named Streptomyces strain Ag18 and Streptomyces strain Ag 20. female albino mice were used in the present study. The mice were divided into 4 groups (6 animals each was control, injected subcutaneously with an isotonic saline solution. The 2nd, injected subcutaneously with Ehrlich ascites tumor cells (EAC). Both the 3rd and 4 injected subcutaneously with Ehrlich ascites tumor cells (EAC) diluted with an isotonic saline solution (SS) tumor formation, (7-10) days after inoculation with EAC cells, animals were locally injected subcutaneous Streptomyces extract, Ag18 and Ag20.The results revealed that only two of the twenty Streptomyces and Ag20) showed their potent antitumor activity against Ehrlich ascites carcinoma cells in vitro. AG18 and AG20 Streptomyces extracts also modulated the mice body weight towards the normal values significantly(p< 0.001) and reduced the tumor volume with a very highly significant change (p< 0.001). The histological study confirmed the above mentioned result, where the kidney and liver of the mice injected with EAC returned to their normal structure after injection with Streptomyces extracts. It is concluded from this study that bioactive product ofStreptomycesAg18 & Ag20 have antitumor activity.


3. Antitumor activity of two Streptomyces extracts (Ag18 & Ag20) on Ehrlich ascites tumor in mice in vitro and in vivo studies.
Download Issue

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *